Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO | ||
By: Nasdaq / GlobeNewswire - 14 Dec 2018 | Back to overview list |
|
Rimiducid-activated GoCAR-T® resulted in significant expansion and persistence of T cells Initial evidence of biologic activity and stable disease observed in some patients with single rimiducid dose BPX-601 was well-tolerated with no CRS or neurotoxicity reported in initial cell-dose escalation Company to add additional tumor types in Part 2 of study, incorporating standard lymphodepletion and repeat rimiducid dosing GENEVA, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported safety and promising activity of BPX-601 in Part 1 of a Phase 1/2 dose-escalation study in patients with advanced, metastatic pancreatic cancer expressing PSCA (prostate stem cell antigen). BPX-601 is a novel GoCAR-T® cell candidate incorporating Bellicum’s co-activation domain, iMC, designed to boost T cell proliferation and persistence via administration of rimiducid. Data were reviewed during an oral presentation at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) held in Geneva, Switzerland from December 13-16. “These initial results in advanced pancreatic cancer suggest that having greater control over the expansion and persistence of therapeutic cells may provide unique treatment benefits. We have observed promising initial clinical activity with BPX-601 in patients with one of the most challenging solid tumors, where there is a critical need for better treatments,” commented Carlos R. Becerra, M.D., lead study investigator and oncologist and medical director of the Innovative Clinical Trials Center at Baylor University Medical Center at Dallas. “I am looking forward to the next phase of our study, which allows for a standard lymphodepletion regimen and administration of multiple doses of rimiducid to further increase the expansion and persistence of BPX-601 cells and the potential for greater impact against pancreatic and other tumor types.” Study Overview Interim Results:
“These results provide the first clinical evidence suggesting that our GoCAR-T technology drives expansion and persistence of therapeutic T cells in patients,” said Rick Fair, President & CEO of Bellicum Pharmaceuticals. “We are excited about BPX-601 and the broader application of our technology intended to improve the safety and efficacy of cell therapies. With these promising results, we’re preparing to begin Part 2 of the BPX-601 study, adding patients with prostate and gastric cancers, allowing multiple doses of rimiducid and a more complete conditioning regimen. We’re looking forward to reporting updated results in 2019.” About BPX-601 Forward-Looking Statement Source: Bellicum Pharmaceuticals CONTACT: Investors: Chad Rubin 646-378-2947 crubin@soleburytrout.com Media: Brad Miles 917-570-7340 bmiles@soleburytrout.com -or- Amy Bonanno 914-450-0349 abonanno@soleburytrout.com |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |